Lepage, C.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 108

Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer

Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 68

Repeat Element Activation-Driven Inflammation: Role of NFκB and Implications in Normal Development and Cancer?

Dumetier, B., Sauter, C., Hajmirza, A., Pernon, B., Aucagne, R., Fournier, C., Row, C., Guidez, F., Rossi, C., Lepage, C., et al. (2022) · Biomedicines

interferon and immune responsesChromosomal and Genetic Variations

Cited by 9

LBA1 Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial

Tougeron, D., Emile, J. F., Bodere, A., Barbier, E., Bez, J., Dourthe, L. M., Perrier, H., Corbinais, S., Le Brun-Ly, V., Bideau, K., et al. (2024) · Annals of Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 6